Trials / Completed
CompletedNCT02660034
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 229 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor BGB-290 (pamiparib) in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tislelizumab | |
| DRUG | Pamiparib |
Timeline
- Start date
- 2016-02-02
- Primary completion
- 2020-09-09
- Completion
- 2020-09-09
- First posted
- 2016-01-21
- Last updated
- 2021-12-06
- Results posted
- 2021-12-06
Locations
29 sites across 6 countries: United States, Australia, France, New Zealand, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02660034. Inclusion in this directory is not an endorsement.